Superworth

Supernus Pharmaceuticals price to book ratio SUPN

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026
2.3×
10-year median
2.2×
Against its 10-year history
55th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.4× to 10.8×
Peer median
3.2×

Supernus Pharmaceuticals' price to book ratio is 2.3× as of Oct 23, 2026.

That is above its ten-year median of 2.2×, close to the middle of its last ten years.

Over that time it ranged from 1.4× in Mar 2020 to 10.8× in Sep 2017.

The median for 10 large drugmakers of a similar size is 3.2×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.3×2.1×3.0×
20252.8×1.7×2.9×
20242.0×1.5×2.1×
20231.7×1.4×2.6×
20222.3×1.7×2.4×
20211.9×1.6×2.3×
20201.9×1.4×2.3×
20192.2×2.0×4.8×
20184.0×3.8×9.6×
20178.1×7.3×10.8×
20168.9×5.0×9.2×
20156.0×5.3×10.7×
20145.6×5.5×27.4×
201321.6×2.6×21.6×
20127.1×7.1×12.2×

Against its peers

Companies in Drug Manufacturers - General nearest Supernus Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
SUPNSupernus Pharmaceuticals2.3×
PBHPrestige Consumer Healthcare1.2×
HRMYHarmony Biosciences2.1×
NRIXNurix Therapeutics2.9×
ANIPANI Pharmaceuticals2.8×
PAHCPhibro Animal Health4.1×
OGNOrganon3.6×
LQDALiquidia19.6×
ANABAnaptysbio138×
PCRXPacira BioSciences2.2×
ARQTArcutis Biotherapeutics17.8×
Peer median3.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Supernus Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.